Cargando…
Immunotherapy for Renal Cell Carcinoma
Immunotherapy plays a significant role in the management of renal cell carcinoma (RCC) patients with metastatic disease because RCC is highly resistant to both chemotherapy and radiation therapy. Many reports illustrate various approaches to the treatment of RCC, such as cytokine-, antigen- or dendr...
Autores principales: | Itsumi, Momoe, Tatsugami, Katsunori |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3022170/ https://www.ncbi.nlm.nih.gov/pubmed/21253521 http://dx.doi.org/10.1155/2010/284581 |
Ejemplares similares
-
Equol inhibits prostate cancer growth through degradation of androgen receptor by S‐phase kinase‐associated protein 2
por: Itsumi, Momoe, et al.
Publicado: (2016) -
Efficacy and safety of sorafenib for advanced renal cell carcinoma: real-world data of patients with renal impairment
por: Tatsugami, Katsunori, et al.
Publicado: (2018) -
Impact of inflammation and immunotherapy in renal cell carcinoma
por: Shi, Jian, et al.
Publicado: (2020) -
Immunotherapy in Renal Cell Carcinoma: The Future Is Now
por: Deleuze, Antoine, et al.
Publicado: (2020) -
Prognosis of Japanese patients with previously untreated metastatic renal cell carcinoma in the era of molecular-targeted therapy
por: Shinohara, Nobuo, et al.
Publicado: (2015)